Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

This article was originally published in The Tan Sheet

Executive Summary

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

You may also be interested in...



Petition To Restrict St. John’s Wort Draws Fire From Industry

Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.

Petition To Restrict St. John’s Wort Draws Fire From Industry

Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.

Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman

Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel